Navigation Links
Scripps Research Institute receives $20 million to shed light on HIV drug resistance
Date:9/19/2012

LA JOLLA, CA, September 19, 2012 The Scripps Research Institute has received a grant totaling approximately $20 million over five years from the National Institutes of Health to research the development of drug resistance in HIV, the virus that causes AIDS.

The grant will create a new consortium, the HIV Interaction and Viral Evolution (HIVE) Center, to better understand drug resistance and lay the groundwork for developing new anti-HIV treatments.

"We're excited about the project," said Scripps Research Professor Arthur Olson, PhD, who is principal investigator of the new center. "Using HIV, we aim to develop a broad methodology to develop drugs in the context of the evolution of drug resistance. In the process, we'll pursue any new anti-HIV drug, combination, or approach we find that is robust in the face of drug resistance as a potential treatment regimen."

"This center brings together an impressive team of virologists and structural biologists to investigate the structure and function of HIV, including how it responds to the selective pressure imposed by the drugs used in AIDS therapy," said Michael Sakalian, PhD, the official who oversees the grant at the NIH National Institute of General Medical Sciences, which made the award with the National Institute of Allergy and Infectious Diseases. "Their efforts, which focus on elements of the virus that have been difficult to study, will further our understanding of host-pathogen interactions and ways to combat drug resistance."

The current effort grew out of Olson's 15 years of research on HIV protease, a viral enzyme that is a target for several anti-HIV drugs. While the laboratory had been making progress on this avenue of research, Olson realized that all three of the virus's enzymesprotease, integrase, and reverse transcriptasewere interacting as the virus mutated.

"A virus is a complex system, especially HIV, and there are all kinds of interplay between different drug targets," noted Olson. "There's a lot we don't know about how these enzymes interact with each other, other proteins, and human proteins."

To help fill in these gaps, Olson decided to propose a center to look at the evolution of resistance in the life cycle of the entire virus. He began reaching out to researchers with complementary specialties in the field of HIV research.

The result is a group of top researchers from across the country who will collaborate as part of the HIVE Center. The team includes: Edward Arnold, Ronald Levy, Roger Jones, and Joseph Marcotrigiano of Rutgers University; Alan N. Engelman of the Dana Farber Cancer Institute; Michael Parniak of the University of Pittsburgh; Mamuka Kvaratskhelia of Ohio State University; Alan Rein and Stephen Hughes of the National Cancer Institute-Frederick; and Richard K. Belew of Electronic Artifacts.

The group also includes scientists from both the Florida and California campuses of Scripps Research. On the California campus, joining the center will be David Goodsell, Bruce E. Torbett, Charles D. Stout, Vadim Cherezov, John Elder, and Valery V. Fokin. Contributing expertise from the Florida campus will be Patrick Griffin and Douglas Kotejin.

Olson notes the center will also draw on a clinical component that provides access to records and samples from active-duty military personnel receiving HIV treatment. This will enable the scientists to track changes in the evolution of the viral population under different conditions, including a change in treatment regimen.


'/>"/>
Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Research scientists show how memory B cells stay in class to fight different infections
2. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
3. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
4. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
5. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
6. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
7. NIH awards $20 million over 5 years to train next generation of global health researchers
8. Researchers develop a new cell and animal model of inflammatory breast cancer
9. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
10. Sexually abused boys at risk for more unsafe sex: UBC research
11. Researchers Find Gene Mutations That May Be a Key to Autism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research Institute receives $20 million to shed light on HIV drug resistance
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: